Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity
Oisín Kavanagh,
Fiona Hogan,
Caoimhe Murphy,
Denise Croker,
Gavin Walker
Affiliations
Oisín Kavanagh
Solid State Pharmaceutical Centre (SSPC), The Science Foundation Ireland Research Centre for Pharmaceuticals, Department of Chemical Sciences, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland
Fiona Hogan
Solid State Pharmaceutical Centre (SSPC), The Science Foundation Ireland Research Centre for Pharmaceuticals, Department of Chemical Sciences, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland
Caoimhe Murphy
Solid State Pharmaceutical Centre (SSPC), The Science Foundation Ireland Research Centre for Pharmaceuticals, Department of Chemical Sciences, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland
Denise Croker
Solid State Pharmaceutical Centre (SSPC), The Science Foundation Ireland Research Centre for Pharmaceuticals, Department of Chemical Sciences, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland
Gavin Walker
Solid State Pharmaceutical Centre (SSPC), The Science Foundation Ireland Research Centre for Pharmaceuticals, Department of Chemical Sciences, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland
Mannitol infusion is commonly used in the treatment of intracranial hypertension following traumatic brain injury. It has long been known to have stability issues, specifically, mannitol recrystallises from solutions greater than 10% w/v in ambient conditions. This can happen at any time, whether on the pharmacy shelf or during a medical procedure. This study describes the stability limits of 20% w/v mannitol infusion (the most common strength used clinically) and proposes a number of safer, stable and tuneable hyperosmotic formulations of mannitol in combination with clinically acceptable osmotic agents (NaCl, sorbitol and glycerol).
